| (Values in U.S. Thousands) | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 |
| Sales | 0 | 0 | 0 | 0 | 650 |
| Sales Growth | unch | unch | unch | -100.00% | unch |
| Net Income | -81,310 | -57,880 | -35,930 | -53,960 | -24,420 |
| Net Income Growth | -40.48% | -61.09% | +33.41% | -120.97% | unch |
Cybin Inc (HELP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Helus Pharma is a clinical stage pharmaceutical company. Its lead candidate includes HLP003 and HLP004. Helus Pharma, formerly known as Cybin Inc., is based in BOSTON.
Fiscal Year End Date: 03/31